Jardiance diabetes
Pro Research Analysisby 
Searched over 200M research papers for "jardiance diabetes"
Jardiance (Empagliflozin) for Type 2 Diabetes: Efficacy, Safety, and Additional Benefits
Introduction to Jardiance (Empagliflozin)
Jardiance, known generically as empagliflozin, is a sodium-glucose cotransporter-2 (SGLT2) inhibitor used primarily for the treatment of type 2 diabetes mellitus (T2DM). This medication works by inhibiting the reabsorption of glucose in the kidneys, promoting its excretion through urine, and thereby lowering blood glucose levels 123.
Efficacy in Glycemic Control
Empagliflozin has been shown to effectively improve glycemic control in adults with T2DM. Clinical trials have demonstrated that empagliflozin significantly reduces glycated hemoglobin (HbA1c) levels, fasting, and postprandial glucose levels 237. The drug's efficacy is comparable to other antidiabetic agents such as metformin, glimepiride, and sitagliptin, with the added benefits of weight reduction and lower blood pressure 37.
Cardiovascular and Renal Benefits
One of the standout features of empagliflozin is its cardioprotective and renoprotective properties. The EMPA-REG OUTCOME trial highlighted that empagliflozin significantly reduces the risk of cardiovascular death and hospitalization for heart failure in patients with T2DM and established cardiovascular disease 235. Additionally, it has been approved to reduce the risk of cardiovascular death and hospitalization in adults with heart failure, even in those without diabetes 8.
Safety Profile and Side Effects
Empagliflozin is generally well tolerated, with most adverse events being mild to moderate. Common side effects include mycotic genital infections, particularly in women, and a slight increase in urinary tract infections 37. There is a low risk of hypoglycemia unless empagliflozin is used in combination with insulin or sulfonylureas 27. However, there are warnings regarding the risk of ketoacidosis and acute kidney injury, necessitating careful monitoring in certain patient populations 45.
Use in Pediatric Patients
Empagliflozin has recently been approved for use in children aged 10 years and older, expanding its utility beyond adult patients 1. This approval underscores the drug's versatility and potential to address glycemic control in younger populations with T2DM.
Potential Dual Benefits for Neurological Disorders
Emerging research suggests that empagliflozin may also have potential benefits in treating neurological disorders associated with diabetes, such as Alzheimer's disease. Studies indicate that empagliflozin can act as a dual inhibitor against acetylcholinesterase and beta-secretase, enzymes implicated in Alzheimer's disease, thus offering a novel therapeutic approach for diabetes-associated neurological conditions 6.
Conclusion
Empagliflozin (Jardiance) is a valuable addition to the therapeutic arsenal for managing type 2 diabetes, offering significant benefits in glycemic control, cardiovascular protection, and potential renal benefits. Its safety profile is favorable, though clinicians should be vigilant about specific risks such as ketoacidosis and renal impairment. The recent approval for pediatric use and potential neurological benefits further enhance its clinical utility.
Sources and full results
Most relevant research papers on this topic
Empagliflozin (Jardiance) for type 2 diabetes in children.
Empagliflozin and metformin are now approved for use in children 10 years old with type 2 diabetes to improve glycemic control.
[EMPAGLIFLOZIN (JARDIANCE) :Nw SGLT2 COTRANSPORTER INHIBITOR FOR TREATING TYPE 2 DIABETES].
Empagliflozin effectively treats type 2 diabetes by reducing blood sugar levels and weight, while also promoting weight reduction and lowering arterial blood pressure.
RCTA Case of Severe Metabolic Acidosis due to Jardiance-Induced Euglycemic Diabetic Ketoacidosis
Empagliflozin, a type 2 diabetes drug, can cause severe euglycemic diabetic ketoacidosis in patients with acute illness, decreased carbohydrate intake, or discontinuing insulin.
Case Report
Rigorous JournalDiabetes Drug Receives New Indication.
Empagliflozin, a type 2 diabetes drug, has been approved to reduce cardiovascular death in patients with established cardiovascular disease, but it carries a risk of ketoacidosis and acute kidney injury.
Prediction of Anti-Diabetic Drugs as Dual Inhibitors Against Acetylcholinesterase and Beta-Secretase: A Neuroinformatics Study.
Anti-diabetic drugs (Jardiance, Suiny, and Nesina) show potential as dual inhibitors against acetylcholinesterase and beta-secretase, potentially benefiting treatment of diabetes-associated neurological disorders.
In Vitro StudyEmpagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Empagliflozin, a once-daily treatment for adult patients with type 2 diabetes, improves blood glucose control and reduces bodyweight and systolic blood pressure when combined with other antidiabetic drugs.
Literature ReviewDiabetes Drug Now Approved for Heart Failure.
Empagliflozin reduces cardiovascular death and hospitalization risk in adults with heart failure, even if they do not have diabetes.
Three new treatments for diabetes recommended by NICE
NICE recommends canagliflozin, dapagliflozin, and empagliflozin as treatment options for adults with type 2 diabetes when metformin, sulfonylurea, or pioglitazone are contraindicated or not tolerated.
Rigorous Journal